Shares of US biotech company Exact Science are up nearly 90% this year. But the race may not be over yet, according to fund manager Dani Saurymper. Nasdaq-listed company performs tests to detect colon cancer. Earlier this week, they said their next-generation screening test, Cologuard 2.0, showed a 30% lower false-positive rate when detecting the disease in one study than the approved test. The positive results from the study, called BLUE-C, come at a pivotal time for the company. According to Saurymper, Pacific Asset Management’s Longevity and Social Change fund manager, millions of screenings have not taken place during the Covid-19 pandemic, which has created significant demand for the testing technology. by Exact Science. “It’s a huge opportunity. And someone like Exact is clearly taking advantage of that opportunity,” Saurymper told CNBC’s Pro Talks on Wednesday. The Saurymper Fund EXAS 1Y Series is focused on identifying investment opportunities among companies with high exposure to an aging demographic, which Saurymper calls “the enduring industry.” Their screening method involves examining companies’ revenue streams and ranking them based on how much of their income is generated from these industries. Companies with more than half of their revenue from these sectors are considered high-risk. One topic that Saurymper highlights with investors is disease prevention and screening. He believes it is more beneficial to focus on companies that promote healthy lifestyles and prevent disease than focus on companies that provide treatments. This is where Exact Science fits in. The company, once a loss, has seen a significant increase in screening volume and is expected to be profitable this year. Last year, the company’s screening business brought in $1.4 billion in revenue, mostly from sales of FDA-approved colon cancer tests. Analysts have also welcomed the new study’s results. Kyle Mikson, an analyst at Canaccord Genuity, said: “Overall, we believe Exact’s BLUE-C top results for next-generation Cologuard are remarkable (and relatively solid). “. customers on June 20. In addition, Exact Science is also developing a “liquid biopsy,” designed to use a blood test to detect early signs of liver cancer, which can then extended to detect other forms in the future. While investors welcome the stock’s rally this year, Exact stock has suffered losses over the past two years along with other tech stocks. Saurymper believes the stock has corrected and has a significant road ahead. “Its fundamentals have caught up with the stock price,” he told CNBC’s Arabile Gumede. “We definitely think it has significant growth ahead and we’re not going to back down.”